Skip to main content

Table 3 HIV-1 integration events in control and Raltegravir-treated SupT1 cells (a)

From: Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polyprotein

Sequence

amplified

Raltegravir (nM)

 

0

1

10

100

Alu-gag junctions

26.9 ± 0.2

36.1 ± 0.3

ND

ND

GAPDH

23.3 ± 0.5

23.7 ± 0.4

24.1 ± 0.3

23.9 ± 0.2

  1. (a) Aliquots of HIV-1-infected SupT1 cells were pretreated with Raltegravir at 0, 1, 10, and 100 nM, respectively, for 24 hr prior to HIV-1 infection (MOI 10), and the drug maintained at the indicated concentrations for 7 days. Host cell genomic DNA was extracted on day 7 pi, and the level of HIV-1 integration in SupT1 cell lines was evaluated by quantitative PCR amplification of DNA extracts, using primers specific to Alu-gag junctions and to cellular GAPDH gene as the internal control. Figures shown in the Table are Cts values (mean ± SD, n = 3). ND, not detectable (below the threshold of detection).